Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Abstract Text:

Todd P Gilmer,Christian R Dolder,David P Folsom,William Mastin,Dilip V Jeste,

OBJECTIVE: This study examined trends and costs of second-generation antipsychotic polypharmacy among Medicaid beneficiaries with schizophrenia in San Diego County. METHODS: Medicaid data were used to identify 15,962 persons with schizophrenia receiving antipsychotic medications between 1999 and 2004. The yearly proportion of beneficiaries receiving second-generation antipsychotic polypharmacy, duration of polypharmacy, inpatient admissions, and pharmaceutical costs were examined. RESULTS: The proportion of clients receiving second-generation antipsychotic polypharmacy increased from 3.3% in 1999 to 13.7% in 2004, whereas annual antipsychotic medication costs increased from $4,128 to $5,231 (2004 dollars). Among those receiving second-generation polypharmacy, the percentage receiving second-generation polypharmacy for 12 months increased from 5.1% to 14.4%, and the percentage hospitalized increased from 7.2% to 9.0%. CONCLUSIONS: The prevalence of long-term second-generation antipsychotic polypharmacy and its associated costs increased substantially between 1999 and 2004. Prescribing antipsychotic polypharmacy is an unproven and costly strategy that if left unchanged could lead to administrative efforts to cut costs and dictate practice.

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Publishing Authors By Initials

TP Gilmer,CR Dolder,DP Folsom,W Mastin,DV Jeste,

For similar mental disorders: schizophrenia and disorders with psychotic features: schizophrenia research abstracts see: mental disorders: schizophrenia and disorders with psychotic features: schizophrenia research

PUBMED ID PMID:

MEDLINE DATE:

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Psychiatric services (Washington, D.C.)

VOLUME: 58

Page Numbers: 1007-10

Journal Abbreviation:

ISSN: 1075-2730

DAY: 3

MONTH: Jul

YEAR: 2007

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502838

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Keywords Mesh Terms:

KEYWORDS: Schizophrenia

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Information

Substance Name: Antipsychotic Agents

Registry Number: 0

Grant and Affiliation Information for Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.

AFFILIATION: Department of Family and Preventive Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0622, USA. tgilmer@ucsd.edu

Country: United States

AGENCY: United States NIMH

GRANT: P30-MH-066248

ACRONYM: MH

MEDLINETA: Psychiatr Serv

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004 Related Publications

• A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial.
• A review of performance-based measures of functional living skills.
• Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
• Anxiety disorders in a public mental health system: Clinical characteristics and service use patterns.
• Assessment of medication management ability in middle-aged and older adults with bipolar disorder.
• Brain response correlates of decisional capacity in schizophrenia: a preliminary FMRI study.
• Complementary and alternative medicine (CAM) use in geriatric psychiatry clinics.
• Complementary and alternative treatments for late-life depression, anxiety, and sleep disturbance: a review of randomized controlled trials.
• Costs of community-based public mental health services for older adults: variations related to age and diagnosis.
• Cultural formulation with attention to language and cultural dynamics in a mexican psychiatric patient treated in san diego, california.
• Deficits in cue detection and intention retrieval underlie prospective memory impairment in schizophrenia.
• Diagnostic variability for schizophrenia and major depression in a large public mental health care system dataset.
• Enhancing the informed consent process: a conceptual overview.
• Functional adaptation skills training (FAST): a randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders.
• Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients.
• Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
• Initiation and use of public mental health services by persons with severe mental illness and limited english proficiency.
• Medication adherence skills training for middle-aged and elderly adults with bipolar disorder: development and pilot study.
• Multivariate predictors of social skills performance in middle-aged and older out-patients with schizophrenia spectrum disorders.
• Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia.
• Neuropsychological predictors of functional outcome in Cognitive Behavioral Social Skills Training for older people with schizophrenia.
• Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects.
• Preliminary report: cerebral blood flow abnormalities in older schizophrenic patients.
• Public-academic partnerships: improving care for older persons with schizophrenia through an academic-community partnership.
• Publication of the International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.
• Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up.
• Recent advances in research on successful or healthy aging.
• Self-administered cognitive screening for a study of successful aging among community-dwelling seniors: a preliminary study.
• Successful aging: from phenotype to genotype.
• Unmet needs for mental health services for latino older adults: perspectives from consumers, family members, advocates, and service providers.